Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 1998

View Archived Issues

Company Profile: Millennium

Clinical development of LM-AS-013 advances at Green Cross

Inhibitors of the production or release of sCD23, TNF

Dopamine D4 receptor antagonists for imaging and therapy disclosed by Janssen

New excitatory amino acid antagonists in development at Pfizer

Meiji Seika describes 5-HT3 partial agonists for GI disorders

Triangle reports results from phase I/II FTC trial

Tsumura team reveals semisynthetic huperzine derivatives

More new agents for influenza from Lilly

PMPA reduces viral load in phase I/II

Potent, orally active inhibitor of kynurenine 3-hydroxylase discovered at Roche

Diphenylalkylamine derivative with cardioprotective properties characterized

ArQule and CuraGen establish broad drug discovery collaboration

Comparative trial of intracavernous alprostadil and MUSE for ED

Swiss Remune trials initiated

Long-term efficacy of epoprostenol for primary pulmonary hypertension

Optison imaging agent launched in U.S.

FDA advisory committee recommends Integrilin approval

Hybridon antitumor antisense compound enters clinical trials

Folic acid therapy and cardiovascular risk reduction

Anesta signs European marketing agreement for Actiq

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...